Bristol Myers Squibb to present new cardiovascular data at ESC Congress 2025

Bayer confirms 2025 targets after solid start to the year

EBITDA before special items decreases to €4.08 billion (7.4%)

We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer

Bayer expects 2025 to be the most difficult year of its turnaround

Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility

The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities

Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion

Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings

Roche launches three new Factor Xa inhibitor coagulation tests

The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention

Venus Remedies expands global presence with marketing authorisation for enoxaparin from Azerbaijan

The company makes its maiden entry into Azerbaijan’s pharmaceutical market

Oceanic-AF study stopped early due to lack of efficacy

OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program

Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke